Here, we report that the GFI1-dependent and p53-independent modulation of sphingolipid metabolism promotes MM cell survival, as well as the enhancement of MM cell growth and drug resistance induced by the BM microenvironment. The gene discussed is TP53; the disease is Miyoshi myopathy.